In this study, the efficacy of bicalutamide addition, a second-generation AR antagonist that is widely used in prostate cancer, to conventional chemotherapy (doxorubicin and docetaxel) used in breast cancer has been evaluated for IMC and IBC [15,19,39,40]. This evidence concerns the gene AR and breast carcinoma.